Education
About Us
Working with TipRanks
Follow Us
Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$55.42M
Enterprise ValueS$131.79M
Total Cash (Recent Filing)S$3.85M
Total Debt (Recent Filing)S$88.57M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,231,494,600
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe company reported ~95% top-line growth, indicating strong demand or successful market expansion. Sustained revenue expansion improves operating leverage and scale, enabling investment in service lines and efficiencies that can materially lift margins and long-term profitability.
Improving Free Cash Flow TrendA 91% free cash flow growth rate signals improving cash conversion trends even though absolute cash flows remain negative. A durable upward FCF trend can precede a shift to positive operating cash flow if revenue growth continues and cost structure tightens, aiding future self-funding.
Equity Base StabilityA relatively stable equity ratio provides a financial cushion against shocks and supports access to credit. This stability reduces immediate solvency pressure, giving management time to execute strategic improvements without forced dilutive capital raises in the near-to-medium term.
Bears Say
Persistent UnprofitabilityConsistent negative net and EBIT margins reflect structural unprofitability. Ongoing losses erode shareholder equity and depress ROE, limiting retained earnings and operational reinvestment capacity, thereby requiring external funding unless margins are materially improved.
Negative Operating Cash FlowNegative operating cash flow indicates core operations consume cash rather than generate it. This weakens the company's ability to fund working capital and capex internally, increases reliance on external financing, and elevates liquidity and refinancing risk over the medium term.
High LeverageA debt-to-equity ratio above 1.0 signals meaningful leverage that increases interest obligations and reduces financial flexibility. High leverage constrains ability to invest in growth, raises default risk in downturns, and can force priority on deleveraging over strategic initiatives.
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$55.42M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 251 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on Feb 13, 2026. The company reported -S$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.009.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,231,494,600 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-39.37%
Trailing 12-Months
Asset Growth
-10.12%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.